New diabetes drug tested in patients with kidney trouble

NCT ID NCT05374343

First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time

Summary

This early-phase study looked at how the drug rongliflozin works in 32 Chinese adults with type 2 diabetes who have normal, mildly, or moderately reduced kidney function. Researchers measured drug levels in the blood and how much sugar was passed in urine after a single dose. The goal was to understand how kidney function affects the drug's action and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ping Feng

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.